Alzheimer's disease (AD) is characterized by extraneuronal plaques consisting of b-amyloid (A?) peptides and intracellular neurofibrillary tangles (NFTs) composed of hyperphosphorylated, paired helical filaments of the microtubule-associated protein, tau. Multiple lines of evidence suggest that overproduction of A? in the brain is a major cause of AD, whereas hyperphosphorylated tau has been found in many neurodegenerative diseases known as tauopathies. Hence, identification of new genes/proteins involved in these processes is a major goal in AD research and may provide potential therapeutic targets. In the previous funding period, we applied the random homozygous gene perturbation (RHGP) technology to screen for genes involved in A? generation and identified a novel mouse gene, Rps23r1(previously named Fg01 in the original submission). Overexpression of the RPS23R1 protein can significantly reduce A? generation, tau phosphorylation and GSK-3 activity. Further in vitro studies showed that RPS23R1 interacts with adenylate cyclases, increasing cAMP synthesis, which upregulates PKA activity. Both activation of PKA and inactivation of GSK-3 are known to inhibit A? generation and GSK-3 inactivation also inhibits tau phosphorylation. The function of Rps23r1 was also demonstrated in transgenic mice expressing brain-specific Rps23r1. Furthermore, the AD-like pathologies of the APP/PS1/tau triple transgenic AD mice were ameliorated and levels of synaptic marker proteins were increased after crossing the mice with the Rps23r1 transgenic mice. Although Rps23r1 is a unique mouse gene, Rps23r1 produces the same phenotype in cells of various species including human. Rps23r1 originated through mouse Rps23 (ribosomal protein S23) mRNA retroposition, a process where mRNA is reintegrated into the genome resulting in gene duplication/evolution. Since Rps23 retroposition also occurred in humans, it is possible that humans possess functional Rps23r1 homologs. Our results suggest that RPS23R1- and functional human RPS23R1 homolog-mediated signaling pathways may play important roles in the pathogenesis of AD and other diseases, such as cancer and diabetes, in which PKA and GSK-3 are crucially involved. Therefore, in this competitive renewal proposal we aim to determine the functional domain(s) of RPS23R1, identify functional human Rps23r1 homologs, further characterize RPS23R1 and its human homologs and decipher mechanisms underlying their effects, specifically inhibition of A generation, tau phosphorylation and modulation of GSK-3 activity. We will cross brain-specific Rps23r1 transgenic mice with AD transgenic (Tg2576 and APP/PS1/tau triple) mice to determine whether Rps23r1 can ameliorate AD-like pathologies and behavioral/cognitive deficits. We will also generate Rps23r1 conditional knockout mice to explore other physiological functions of Rps23r1. The results of these studies are expected to provide important information for developing new strategies to combat AD and other diseases.

Public Health Relevance

Alzheimer's disease (AD) is a devastating neurodegenerative disease characterized by extraneuronal plaques resulting from Ab and NFTs caused by tau phosphorylation. Our identification of the novel gene, Rps23r1, and the molecular pathway/mechanism by which it reduces Ab generation and tau phosphorylation, is expected to have a significant impact on basic research and development of new strategies for treating AD.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG021173-07
Application #
8443819
Study Section
Cell Death in Neurodegeneration Study Section (CDIN)
Program Officer
Miller, Marilyn
Project Start
2002-07-01
Project End
2016-02-29
Budget Start
2013-04-15
Budget End
2014-02-28
Support Year
7
Fiscal Year
2013
Total Cost
$377,764
Indirect Cost
$184,039
Name
Sanford-Burnham Medical Research Institute
Department
Type
DUNS #
020520466
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Zhu, Bing; Jiang, LuLin; Huang, Timothy et al. (2017) ER-associated degradation regulates Alzheimer's amyloid pathology and memory function by modulating ?-secretase activity. Nat Commun 8:1472
Wu, Xi-Lin; PiƱa-Crespo, Juan; Zhang, Yun-Wu et al. (2017) Tau-mediated Neurodegeneration and Potential Implications in Diagnosis and Treatment of Alzheimer's Disease. Chin Med J (Engl) 130:2978-2990
Huang, Timothy Y; Zhao, Yingjun; Jiang, Lu-Lin et al. (2017) SORLA attenuates EphA4 signaling and amyloid ?-induced neurodegeneration. J Exp Med 214:3669-3685
Huang, Timothy Y; Zhao, Yingjun; Li, Xiaoguang et al. (2016) SNX27 and SORLA Interact to Reduce Amyloidogenic Subcellular Distribution and Processing of Amyloid Precursor Protein. J Neurosci 36:7996-8011
Wang, Chen; Niu, Mengxi; Zhou, Zehua et al. (2016) VPS35 regulates cell surface recycling and signaling of dopamine receptor D1. Neurobiol Aging 46:22-31
Zheng, Qiuyang; Huang, Timothy; Zhang, Lishan et al. (2016) Dysregulation of Ubiquitin-Proteasome System in Neurodegenerative Diseases. Front Aging Neurosci 8:303
Wang, Xin; Zhou, Ying; Wang, Jian et al. (2016) SNX27 Deletion Causes Hydrocephalus by Impairing Ependymal Cell Differentiation and Ciliogenesis. J Neurosci 36:12586-12597
Zhang, Cuilin; Shi, Zhun; Zhang, Lingzhi et al. (2016) Appoptosin interacts with mitochondrial outer-membrane fusion proteins and regulates mitochondrial morphology. J Cell Sci 129:994-1002
Feng, Tuancheng; Niu, Mengmeng; Ji, Chengxiang et al. (2016) SNX15 Regulates Cell Surface Recycling of APP and A? Generation. Mol Neurobiol 53:3690-3701
Barini, Erica; Antico, Odetta; Zhao, Yingjun et al. (2016) Metformin promotes tau aggregation and exacerbates abnormal behavior in a mouse model of tauopathy. Mol Neurodegener 11:16

Showing the most recent 10 out of 52 publications